Linezolid for therapy of


Journal

Infectious diseases (London, England)
ISSN: 2374-4243
Titre abrégé: Infect Dis (Lond)
Pays: England
ID NLM: 101650235

Informations de publication

Date de publication:
11 2020
Historique:
pubmed: 11 7 2020
medline: 22 4 2021
entrez: 11 7 2020
Statut: ppublish

Résumé

Linezolid has good penetration to the meninges and could be an alternative for treatment of Retrospective multicenter cohort study of 26 adults treated with linezolid, derived from a cohort of 350 cases of There were 15 males (58%) and mean age was 47.3 years. Meningitis was postoperative in 21 (81%) patients. The infection was nosocomial in 23 (88%) cases, and caused by methicillin-resistant Linezolid appears to be effective and safe for therapy of

Sections du résumé

BACKGROUND
Linezolid has good penetration to the meninges and could be an alternative for treatment of
METHODS
Retrospective multicenter cohort study of 26 adults treated with linezolid, derived from a cohort of 350 cases of
RESULTS
There were 15 males (58%) and mean age was 47.3 years. Meningitis was postoperative in 21 (81%) patients. The infection was nosocomial in 23 (88%) cases, and caused by methicillin-resistant
CONCLUSIONS
Linezolid appears to be effective and safe for therapy of

Identifiants

pubmed: 32648796
doi: 10.1080/23744235.2020.1789212
doi:

Substances chimiques

Anti-Bacterial Agents 0
Linezolid ISQ9I6J12J

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

808-815

Auteurs

Vicente Pintado (V)

Infectious Diseases Service, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.

Rosario Pazos (R)

Infectious Diseases Service, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
Department of Biomedical Sciences and Medicine, Universidade do Algarve, Faro, Portugal.

Manuel Enrique Jiménez-Mejías (ME)

Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville (IBIS), University of Seville/CSIC/University Hospital Virgen del Rocío, Seville, Spain.

Azucena Rodríguez-Guardado (A)

Infectious Diseases Unit, Hospital Central de Asturias, Oviedo, Spain.

Beatriz Díaz-Pollán (B)

Infectious Diseases Unit/Department of Internal Medicine, Hospital La Paz, Madrid, Spain.

Carmen Cabellos (C)

Infectious Diseases Service, Hospital Bellvitge, L'Hospitalet, Barcelona, Spain.

Juan Manuel García-Lechuz (JM)

Clinical Microbiology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Department of Clinical Microbiology, Hospital Gregorio Marañon, Madrid, Spain.

Jaime Lora-Tamayo (J)

Internal Medicine Department, Hospital 12 de Octubre, Madrid, Spain.

Pere Domingo (P)

Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Elena Muñez (E)

Infectious Diseases Unit, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.

Diego Domingo (D)

Microbiology Service, Hospital de La Princesa, Madrid, Spain.

Fernando González-Romo (F)

Clinical Microbiology Service, Hospital Clínico San Carlos, Madrid, Spain.

José Antonio Lepe-Jiménez (JA)

Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville (IBIS), University of Seville/CSIC/University Hospital Virgen del Rocío, Seville, Spain.

Carlos Rodríguez-Lucas (C)

Infectious Diseases Unit, Hospital Central de Asturias, Oviedo, Spain.

Eulalia Valencia (E)

Infectious Diseases Unit/Department of Internal Medicine, Hospital La Paz, Madrid, Spain.

Iván Pelegrín (I)

Infectious Diseases Service, Hospital Bellvitge, L'Hospitalet, Barcelona, Spain.

Fernando Chaves (F)

Clinical Microbiology Department, Hospital 12 de Octubre, Madrid, Spain.

Virginia Pomar (V)

Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Antonio Ramos (A)

Infectious Diseases Unit, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.

Teresa Alarcón (T)

Microbiology Service, Hospital de La Princesa, Madrid, Spain.

Elisa Pérez-Cecilia (E)

Clinical Microbiology Service, Hospital Clínico San Carlos, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH